Shortly after the U.S. FDA announced an investigation into the death of a patient who had received Elevidys, a gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT), the company said that the death reported in Brazil is unrelated to its treatment.

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.

The U.S. Food and Drug Administration (FDA) is investigating the death of an eight-year-old boy who received Sarepta Therapeutics (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD).